EGFR and metastatic neoplasm: Likewise, the anti-EGFR free interval >16 months maintained the independent role for PFS (p = 0.020) among the significant variables in the univariate analysis (i.e., long anti-EGFR free interval, previous response to anti-EGFR treatment, and previous lines >2 for metastatic disease).